; (2) manufacturers involved in the research and development of medical countermeasures to address biological, chemical, radiological, and nuclear threats; and (3) other biodefense stakeholders, as applicable. (c) Report Not later than 3 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing the results of the study conducted under subsection (a) and recommendations to improve the application and consistency of the requirements under subsections (c) and (d) of section 565 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–4 ) to support and expedite the research and development of medical countermeasures, as applicable. (d) Protection of national security The Comptroller General of the United States shall conduct the study and issue the assessment and report under this section in a manner that does not compromise national security. VII Miscellaneous provisions 701. Reauthorizations and extensions (a) Veterans Affairs Section 8117(g) of title 38, United States Code, is amended by striking 2014 through 2018 and inserting 2019 through 2023 . (b) Vaccine tracking and distribution Section 319A(e) ( 42 U.S.C. 247d–1(e) ) is amended by striking 2014 through 2018 and inserting 2019 through 2023 . (c) Temporary reassignment Section 319(e)(8) ( 42 U.S.C. 247d(e)(8) ) is amended by striking 2018 and inserting 2023 . (d) Strategic Innovation Partner Section 319L(c)(4)(E)(ix) (42 U.S.C. 247d–7e(c)(4)(E)(ix)) is amended by striking 2022 and inserting 2023 . (e) Public disclosure exemption Section 319L(e)(1)(C) (42 U.S.C. 247d–7e(e)(1)(C)) is amended by striking 12 and inserting 17 . (f) Limited antitrust exemption (1) In general Section 405 of the Pandemic and All-Hazards Preparedness Act (42 U.S.C. 247d–6a note) is amended— (A) by redesignating such section as section 319L–1